CASI Pharmaceuticals
CASI
CASI was delisted on the 25th of February, 2026.
63 hedge funds and large institutions have $50.2M invested in CASI Pharmaceuticals in 2018 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 22 increasing their positions, 10 reducing their positions, and 7 closing their positions.
120% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 10
86% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 7
11% more funds holding
Funds holding: 57 → 63 (+6)
0.1% more ownership
Funds ownership: 1.14% → 1.24% (+0.1%)
38% less capital invested
Capital invested by funds: $80.8M → $50.2M (-$30.6M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$1.33M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.25M |
| 3 |
Charles Schwab
San Francisco,
California
|
+$1.21M |
| 4 |
BlackRock
New York
|
+$1.01M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
+$423K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WSC
Wellington Shields & Co
New York
|
-$383K |
| 2 |
Morgan Stanley
New York
|
-$378K |
| 3 |
RA
Royce & Associates
New York
|
-$288K |
| 4 |
TSS
Two Sigma Securities
New York
|
-$188K |
| 5 |
MC
Moors & Cabot
Boston,
Massachusetts
|
-$187K |
CASI Hedge Fund Activity: Q3 2018 in Review
63 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in CASI Pharmaceuticals (CASI) for Q3 2018, worth a combined $50.2M — down 38% from $80.8M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new CASI positions and 7 closed out — a net gain of 6 holders — while 22 added to existing stakes and 10 trimmed.
The largest buyer was State Street, adding an estimated $1.33M. The largest seller was Wellington Shields & Co, cutting an estimated $383K.
- 63 institutional investors held CASI Pharmaceuticals (CASI) as of Q3 2018, up from 57 in Q2 2018.
- Funds reported $50.2M of CASI Pharmaceuticals stock for Q3 2018, down 38% quarter-over-quarter.
- 13 funds opened new CASI Pharmaceuticals positions in Q3 2018 and 7 closed out, a net change of +6 holders.
- The largest CASI Pharmaceuticals buyer in Q3 2018 was State Street, an estimated $1.33M added.
- The largest CASI Pharmaceuticals seller in Q3 2018 was Wellington Shields & Co, an estimated $383K sold.
Based on aggregated 13F filings for Q3 2018.